• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

    4/6/22 9:58:22 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIXT alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    Lixte Biotechnology Holdings, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    539319 202

     

    (CUSIP Number)

     

    December 17, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall not be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO. 539319 10 3   Page 2 of 5 Pages

     

      1.

    NAMES OF REPORTING PERSONS.

    Glenn Krinsky

         
      2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☒

         
      3. SEC USE ONLY
         
         
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5. SOLE VOTING POWER 1,474,998
         
    6. SHARED VOTING POWER  
         
    7. SOLE DISPOSITIVE POWER 1,474,998
         
    8. SHARED DISPOSITIVE POWER  

     

         
      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON.

    1,474,998(1)

         
         
      10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐
           
           
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.73% (2)

         
      12.

    TYPE OF REPORTING PERSON

    IN

     

     

      (1) Consists of 1,333,333 shares owned of record by the John and Barbara Kovach 2015 Trust of which the Reporting person is the sole Trustee and has voting, dispositive and investment power
      (2) Based on 13,746,593 shares of Common Stock, outstanding as of March 11, 2022.

     

     

     

     

    CUSIP NO. 539319 10 3   Page 3 of 5 Pages

     

    Explanatory Note: On December 17, 2021, the Reporting Person was appointed as successor Trustee of the John and Barbara 2015 Trust.

     

    Item 1(a). Name of Issuer.

     

    The name of the issuer is Lixte Biotechnology Holdings, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.

     

    The address of the Issuer’s principal executive office is 680 East Colorado Boulevard, Suite 180, Pasadena CA 91101.

     

    Item 2(a). Name of Person Filing.

     

    Glenn Krinsky

     

    Item 2(b). Address of Principal Business Office, or, if None, Residence.

     

    680 East Colorado Boulevard, Suite 180, Pasadena CA 91101

     

    Item 2(c). Citizenship.

     

    United States citizen.

     

    Item 2(d). Title of Class of Securities.

     

    The title of the class of securities to which this statement relates is the Common stock, $0.0001 par value per share.

     

    Item 2(e). CUSIP No.

     

    The CUSIP number is 539319-202.

     

    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b) or 13d-2(b), Check Whether the Person Filing is a:

     

    (a) ☐ Broker or dealer registered under Section 15 of the Act
         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Act
         
    (c) ☐ Insurance Company as defined in Section 3(a)(19) of the Act
         
    (d) ☐ Investment Company registered under Section 8 of the Investment Company Act of 1940
         
    (e) ☐ Investment Adviser registered under section 203 of the Investment Advisers Act of 1940
         
    (f) ☐ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
         
    (g) ☐ Parent Holding Company, in accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See Item 7)
         
    (h) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(H).

     

     

     

     

    CUSIP NO. 539319 10 3   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover pages and is incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certifications.

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP NO. 539319 10 3   Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: April 06, 2022
       
      /s/ GLENN KRINSKY
      Glenn Krinsky

     

     

     

    Get the next $LIXT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIXT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIXT
    SEC Filings

    See more
    • Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Other Events

      8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

      5/20/25 4:05:20 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lixte Biotechnology Holdings Inc.

      10-Q - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

      5/12/25 8:30:39 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

      4/18/25 5:25:26 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

      SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

      4/6/22 9:58:22 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

      SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

      4/6/22 9:59:12 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

      3/3/21 7:45:27 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Brown Regina

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      4/2/25 10:36:30 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bernards Rene

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      4/2/25 10:36:27 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Forman Stephen J.

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      4/2/25 10:36:31 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Leadership Updates

    Live Leadership Updates

    See more
    • LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

      PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv

      6/3/24 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

      Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a

      9/26/23 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

      PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization

      6/21/22 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

      4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      10/5/23 8:39:03 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      10/5/23 8:36:30 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

      4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

      10/4/23 6:10:01 PM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

      Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE's Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether "initiated" cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE's proprietary compound LB-100. "In addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new o

      3/31/25 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

      -Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer Immunotherapies- -Two Breakthrough Publications in Medical Journals, EMBO and Cancer Discovery,Supporting LIXTE's Clinical Trial Program- PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities. "C

      3/27/25 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active Form

      -- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company, today announced online publication of new pre-clinical data in BioXriv and International Journal of Pharmaceutics demonstrating how the Company's lead clinical compound, LB-100, is converted into its active form, endothall, a protein phosphatase (PP2A) inhibitor that has been found to be effective in cancer treatment in combination with immunotherapy. As published in BioXriv, scientists at the Netherl

      3/10/25 8:30:00 AM ET
      $LIXT
      Biotechnology: Pharmaceutical Preparations
      Health Care